Quantcast
Home > Quotes > ICPT
ICPT

Intercept Pharmaceuticals, Inc. Common Stock (ICPT) Quote & Summary Data

$93.37
*  
3.73
3.84%
Get ICPT Alerts
*Delayed - data as of Jul. 16, 2018  -  Find a broker to begin trading ICPT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ICPT After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 90.02 / $ 94
1 Year Target
119
Today's High / Low
$ 97 / $ 92.03
Share Volume
583,772
50 Day Avg. Daily Volume
626,457
Previous Close
$ 97.10
52 Week High / Low
$ 135.59 / $ 51.05
Market Cap
2,762,160,508
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -14
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.11

Intraday Chart

Shares Traded

Share Volume:
583,772
50 Day Avg. Daily Volume:
626,457

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -14

Trading Range

The current last sale of $93.37 is 82.90% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 97 $ 135.59
 Low: $ 92.03 $ 51.05

ETFs with ICPT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.47% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +9.73 (10.71%)
0.22% Inspire Small/Mid Cap Impact ETF (ISMD) +2.50 (9.38%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need utilizing our proprietary bile acid chemistry. Our one marketed product, OCA, and portfolio of clinical product candidates have the potential to treat orphan and more prevalent liver diseases for which, currently, there are limited therapeutic solutions. OCA was approved in the United States in May 2016 for use in patients with PBC, under the brand name Ocaliva┬« (obeticholic acid). OCA is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. We believe OCA has broad liver-protective properties and may effectively counter a variety of chronic insults to the liver that cause fibrosis, or scarring, which can eventually lead to cirrhosis, liver transplant and death.  ... More ...  

Risk Grade

Where does ICPT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 97
Open Date:
Jul. 16, 2018
Close Price:
$ 93.37
Close Date:
Jul. 16, 2018

Consensus Recommendation

Analyst Info